390 related articles for article (PubMed ID: 31692920)
21. Advance in bone destruction participated by JAK/STAT in rheumatoid arthritis and therapeutic effect of JAK/STAT inhibitors.
Hu L; Liu R; Zhang L
Int Immunopharmacol; 2022 Oct; 111():109095. PubMed ID: 35926270
[TBL] [Abstract][Full Text] [Related]
22. JAK inhibition in the treatment of inflammatory rheumatic diseases.
Šenolt L
Vnitr Lek; 2023; 69(3):181-188. PubMed ID: 37468313
[TBL] [Abstract][Full Text] [Related]
23. Filgotinib in rheumatoid arthritis.
Westhovens R
Expert Rev Clin Immunol; 2023 Feb; 19(2):135-144. PubMed ID: 36396615
[TBL] [Abstract][Full Text] [Related]
24. Filgotinib in Rheumatoid Arthritis: A Profile of Its Use.
Kim ES; Keam SJ
Clin Drug Investig; 2021 Aug; 41(8):741-749. PubMed ID: 34304373
[TBL] [Abstract][Full Text] [Related]
25. Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib.
Nezamololama N; Fieldhouse K; Metzger K; Gooderham M
Drugs Context; 2020; 9():. PubMed ID: 33240390
[TBL] [Abstract][Full Text] [Related]
26. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
27. Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis.
Cutolo M; Meroni M
J Inflamm Res; 2013 Nov; 6():129-37. PubMed ID: 24453498
[TBL] [Abstract][Full Text] [Related]
28. JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis.
Moura RA; Fonseca JE
Front Med (Lausanne); 2020; 7():607725. PubMed ID: 33614673
[TBL] [Abstract][Full Text] [Related]
29. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
Pope J; Sawant R; Tundia N; Du EX; Qi CZ; Song Y; Tang P; Betts KA
Adv Ther; 2020 May; 37(5):2356-2372. PubMed ID: 32297280
[TBL] [Abstract][Full Text] [Related]
30. Real-Life Comparison of Four JAK Inhibitors in Rheumatoid Arthritis (ELECTRA-
Benucci M; Li Gobbi F; Damiani A; Russo E; Guiducci S; Manfredi M; Lari B; Grossi V; Infantino M
J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38542045
[No Abstract] [Full Text] [Related]
31. Management of Axial Spondyloarthritis - Insights into Upadacitinib.
Braun J; Kiltz U; Baraliakos X
Drug Des Devel Ther; 2022; 16():3609-3620. PubMed ID: 36268520
[TBL] [Abstract][Full Text] [Related]
32. Relative efficacy and safety of Janus kinase inhibitors for the treatment of active psoriatic arthritis: a network meta-analysis.
Lee YH; Song GG
Z Rheumatol; 2023 Jun; 82(5):408-416. PubMed ID: 34716775
[TBL] [Abstract][Full Text] [Related]
33. Phase III trials of JAK1 selective inhibitors in rheumatoid arthritis.
Mysler E; Lizarraga A
Rheumatology (Oxford); 2021 May; 60(Suppl 2):ii17-ii23. PubMed ID: 33950225
[TBL] [Abstract][Full Text] [Related]
34. Evaluating filgotinib for the treatment of rheumatoid arthritis.
Richez C; Truchetet ME
Expert Opin Pharmacother; 2021 Dec; 22(18):2435-2444. PubMed ID: 34402699
[TBL] [Abstract][Full Text] [Related]
35. Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights.
Raimondo MG; Biggioggero M; Coletto LA; Ramming A; Caporali R; Favalli EG
Expert Rev Clin Pharmacol; 2021 Jun; 14(6):661-670. PubMed ID: 33847204
[TBL] [Abstract][Full Text] [Related]
36. Recent developments for new investigational JAK inhibitors in psoriatic arthritis.
Caso F; Costa L; Triggianese P; Maione F; Bertolini N; Vastarella M; Chimenti MS; Tasso M
Expert Opin Investig Drugs; 2023 May; 32(5):361-371. PubMed ID: 37096862
[TBL] [Abstract][Full Text] [Related]
37. JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future.
Angelini J; Talotta R; Roncato R; Fornasier G; Barbiero G; Dal Cin L; Brancati S; Scaglione F
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32635659
[TBL] [Abstract][Full Text] [Related]
38. Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.
Norman P
Expert Opin Ther Pat; 2012 Oct; 22(10):1233-49. PubMed ID: 22971156
[TBL] [Abstract][Full Text] [Related]
39. Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement.
Orsolini G; Bertoldi I; Rossini M
Clin Rheumatol; 2020 Mar; 39(3):727-736. PubMed ID: 31970549
[TBL] [Abstract][Full Text] [Related]
40. English version of Japanese guidance for the use of oral Janus kinase inhibitors (JAK1 and TYK2 inhibitors) in the treatments of psoriasis.
Saeki H; Mabuchi T; Asahina A; Abe M; Igarashi A; Imafuku S; Okubo Y; Komine M; Takahashi K; Torii H; Morita A; Yotsuyanagi H; Watanabe A; Ohtsuki M;
J Dermatol; 2023 May; 50(5):e138-e150. PubMed ID: 37132187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]